Lobuläres vs. duktales Mammakarzinom

Lobuläre Karzinome machen etwa 10–15 % aller Mammakarzinome aus und sind somit der zweithäufigste Brustkrebstyp nach dem intraduktalen Karzinom. Der histologische Typ scheint sich auf die Prognose und auf das Therapieansprechen auszuwirken. Allerdings gibt es dazu noch keine prospektive Studien.

• Literatur

• 1 Marmor S. et al. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer 2017; 123: 3015-3021.
• 2 Metzger-Filho O. et al. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1–98 Trial. J Clin Oncol 2015; 33: 2772-2779.
• 3 Strasser-Weippl K. et al. Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer 2018; 90: 19-25.
• 4 Metzger-Filho O. et al. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol 2013; 31: 1954-1960.
• 5 Finn RS. et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 2016; 18: 67.